Analyzing the Future of Biologic & Biosimilar RA Drugs Market Dynamics 2025-2034: Growth Rate, Trends, and Major Opportunities
Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
What is the Future CAGR of the Biologic & Biosimilar RA Drugs Market, and How Will It Impact Industry Expansion?
In recent times, the market size for biologic & biosimilar ra drugs has experienced significant growth. The market is predicted to climb from $13.99 billion in 2024 to $14.71 billion in 2025, maintaining a compound annual growth rate (CAGR) of 5.2%. Factors such as adoption rates, the outcomes of clinical trials, shifts in market share, long-term patient consequences, and pricing schemes have all contributed to this historic growth.
The market size for biologic and biosimilar RA drugs is forecasted to experience significant growth in the coming years, expanding to $19.51 billion in 2029 with a compound annual growth rate (CAGR) of 7.3%. This growth throughout the projected period can be associated with a rise in the development of biologic drugs, heightened market competition, changes in healthcare policies, patient choices, as well as clinical research and development. There will be notable trends within this forecast period such as increased competition within the biosimilar market, a shift towards personalized medicine and precision therapy, advancements in the drug delivery systems, a heightened emphasis on safety and efficacy, and a move towards patient-centric healthcare.
How Are Key Drivers in the Industry Acting as Catalysts for the Growth of the biologic & biosimilar ra drugs Market?
The surge in the elderly population and the growing occurrence of rheumatoid arthritis are propelling the biologics and biosimilar RA drugs market. The elderly population comprises individuals who are 60 years old or more. Rheumatoid arthritis, an autoimmune disorder, causes the sufferer’s immune system to attack its own healthy cells, predominantly affecting the joints. As the immune system weakens with age, elderly individuals are more prone to this condition. Biologic and biosimilar RA drugs prove significantly more effective in treating rheumatoid arthritis compared to standard drugs. The World Health Organization, a Switzerland-based UN health agency, reported approximately 1 billion people globally over the age of 60 in 2020, and they anticipate this figure will rise to 1.4 billion by 2030, and 2.1 billion by 2050. Additionally, the Centers for Disease Control and Prevention, a US governmental public health agency, estimates the number of US adults living with arthritis will reach 78.4 million by 2040, with around 34.6 million likely to suffer from arthritis-related activity limitations. Consequently, the combined impact of an increasing elderly population and growing rheumatoid arthritis incidence is boosting the biologics and biosimilar RA drugs market.
Request Your Free Biologic & Biosimilar RA Drugs Market Report Sample Now!
https://www.thebusinessresearchcompany.com/sample.aspx?id=9255&type=smp
What Are the Top Market Players Propelling the Growth of the Biologic & Biosimilar RA Drugs Industry?
Major companies operating in the biologic & biosimilar RA drugs market include:
• Samsung BioLogics Co. Ltd._x000D_
• Amgen Inc._x000D_
• Novo Nordisk A/S_x000D_
• AbbVie Inc._x000D_
• Johnson & Johnson Services Inc._x000D_
What Are the Key Trends to Watch in the Biologic & Biosimilar RA Drugs Market Over the Coming Years?
In the market of biologic and biosimilar RA drugs, a key trend driving popularity is the introduction of new innovations. Major players in this market like Organon, a healthcare company based in the U.S., and Samsung Bioepis, a South Korean biopharma company, are concentrating their efforts on developing affordable biosimilar treatments like Dual Concentration Biosimilar Options. As a case in point, in July 2023, these companies launched HADLIMA, a biosimilar of the Humira (adalimumab), in the United States. The availability of HADLIMA in both low and high concentrations is meant to increase accessibility and affordability for patients suffering from autoimmune diseases. With its pricing being 85% cheaper than Humira, it is expected to bring broader patient access. The package of HADLIMA includes an autoinjector – praised by The Arthritis Foundation -alongside the patient support program, “HADLIMA For You” which offers co-pay support and educational resources. It can be used for several conditions including rheumatoid arthritis and Crohn’s disease. The availability of HADLIMA in both citrate-free concentration of 100 mg/mL and citrate-containing low concentration of 50 mg/mL allows for an unbroken continuum of patient care.
Pre-order Your Report for Quick and Easy Delivery!
Which Key Segments Define the Structure of the Biologic & Biosimilar RA Drugs Market and Their Growth Potential?
The biologic & biosimilar RA drugs market covered in this report is segmented –
1) By Source: Microbial, Mammalian, Other Sources
2) By Disease: Oncology, Immunological Disorders, Cardiovascular Disorders, Hematological Disorders, Other Diseases
3) By Manufacturing: Outsourced, In-House
4) By Mode Of Purchase: Prescription Drugs, Over-The-Counter (OTC) Drugs
5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Microbial: Bacterial Sources, Fungal Sources, Yeast Sources
2) By Mammalian: Chinese Hamster Ovary (CHO) Cells, Human Embryonic Kidney (HEK) Cells, Other Mammalian Cell Lines
3) By Other Sources: Plant-Based Sources, Insect-Based Sources, Synthetic Biology Approaches
What Regions Are Dominating the Biologic & Biosimilar RA Drugs Market Growth?
North America was the largest region in the biologic & biosimilar RA drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the biologic & biosimilar RA drugs market report during the forecast period. The regions covered in the biologic & biosimilar ra drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
What Are the Defining Aspects of the Biologic & Biosimilar RA Drugs Market Landscape?
Biologics and biosimilars refer to a class of drugs that are extracted from living organisms such as living cells, microorganisms, and other living creatures. Biosimilars are biologics that have similar characteristics to an already approved biological molecule. These drugs are used for the treatment of rheumatoid arthritis.
Browse Through More Similar Reports By The Business Research Company:
Dermatology Drugs Global Market Report 2022
https://www.thebusinessresearchcompany.com/report/dermatology-drugs-global-market-report
Hematology Drugs Global Market Report 2022
https://www.thebusinessresearchcompany.com/report/hematology-drug-global-market-report
Musculoskeletal Disorders Drugs Global Market Report 2022
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
